Natco Pharma Limited
Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

14th August, 2026

Corporate Relationship Department
M/s. BSE Ltd.
Mumbai – 400 001.
Scrip Code: **524816**

The Manager – Listing
M/s. National Stock Exchange of India Ltd.
MUMBAI – 400 051.
Scrip Code: **NATCOPHARM**

Dear Sir/Madam

Sub: Outcome of the Board Meeting held on 14th August, 2026
Ref: Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015

We would like to inform you that the Board of Directors of the Company at their meeting held today have considered and approved the following along with other items of business:

1. Unaudited Financial Results (Standalone and Consolidated) for the quarter ended 30th June 2026 prepared under Indian Accounting Standards (IND-AS) and as per Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended from time to time (“Listing Regulations”) along with Limited Review Report of the Statutory Auditors. Please find enclosed herewith a copy of the same for your information.

2. Declared interim dividend of Rs.1.50/- (Rupees One Rupees and paise fifty only) (75%) each per equity share of Rs.2/- (Rupees two only) each for the financial year 2026-27. The date for taking on record of its shareholders is eligible for the purpose of payment of interim dividend i.e., record date is fixed as **Thursday, the day of 20th day of August, 2026**. The payment of said interim dividend will start from Wednesday, the day of 26th August, 2026.

3. Evaluating and exploring raising of funds through issuance of equity shares or other securities, including by way of public issue, preferential issue, rights issue, private placement(s), qualified institutions placement(s) and/or any combination thereof or any other method as may be permitted, up to an amount not exceeding ₹2000 Crores (Rupees Two Thousand Crores Only) , in accordance with the applicable provisions of the Companies Act, 2013, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, (each as amended) and any other applicable law, in such manner, and on such terms and conditions as may be deemed appropriate by the Board in its absolute discretion, subject to the receipt of necessary approvals, including the approval of the members of the Company and such other regulatory and statutory approvals as maybe required.

4. Approved the Notice for the 43rd Annual General Meeting and authorised Sri V. C. Nannapaneni, Chairman and Managing Director for fixing the Date & time of the Annual General Meeting for the Financial Year 2025-2026 through Video Conference (VC) / other Audio Visual Means (OAVM).

Natco Pharma Limited
Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

5. The Reconstitution of Risk Management Committee and Environment, Social and Governance Committee of the Company w.e.f. 14th August, 2026.

   The details of the Committee(s) will be available on the website of the Company at https://www.natcopharma.co.in/investor-relations/policies

A Copy of Press release is also enclosed for your information.

Meeting commenced at 12.15 p.m. and concluded at 14.00 p.m.

Thanking you

Yours faithfully,
For NATCO Pharma Limited

VENKAT RAMESH CHEKURI
Digitally signed by VENKAT RAMESH CHEKURI
Date: 2026.08.14 14:03:17 +05'30'

Ch. Venkat Ramesh
Company Secretary &
Compliance Officer

Encl: as above

NATCO Pharma Limited

Regd. Office: Natco House, Road No. 2, Banjara Hills, Hyderabad, Telangana - 500 034.
Phone: +91-40-2354 7532, Website : www.natcopharma.co.in, CIN: L24230TG1981PLC003201

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30-06-2026

(₹ in millions except per share data)

S.No.	Particulars	Quarter ended			Year ended
		30-06-2026	31-03-2026	30-06-2025	31-03-2026
		Unaudited	Audited (Refer note 4)	Unaudited	Audited
	Income				
1	Revenue from operations	7,352	7,391	13,289	40,783
2	Other income	592	778	617	2,976
3	**Total income (1+2)**	**7,944**	**8,169**	**13,906**	**43,759**
4	**Expenses**				
	Cost of materials consumed	1,578	1,028	1,806	5,935
	Purchases of stock-in-trade	278	375	373	2,032
	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(381)	144	151	(1,062)
	Employee benefits expense	1,793	1,585	1,690	6,872
	Finance costs	130	109	32	367
	Depreciation, amortisation and impairment expenses	471	504	576	2,066
	Other expenses	2,219	2,983	3,559	12,641
	Total expenses	**6,088**	**6,728**	**8,187**	**28,851**
5	**Profit before tax and share of profit of associate (3-4)**	**1,856**	**1,441**	**5,719**	**14,908**
6	**Tax expense**				
	(i) Current tax	488	161	1,157	3,035
	(ii) Deferred tax (refer note 9)	146	(1,053)	(241)	(1,846)
	Total tax expense	**634**	**(892)**	**916**	**1,189**
7	**Profit for the period/ year before share of profit of associate (5-6)**	**1,222**	**2,333**	**4,803**	**13,719**
8	Share of profit of associate (net of tax)	843	357	-	466
9	**Profit for the period/ year (7+8)**	**2,065**	**2,690**	**4,803**	**14,185**
10	**Other comprehensive income/ (loss) ('OCI') (net of tax)**				
	(i). Items that will not be reclassified to profit or loss:				
	Remeasurement of defined benefit liability/(asset)	1	19	-	19
	Tax on remeasurement of defined benefit liability/(asset)	-	(7)	-	(7)
	Fair value changes of Equity investments through OCI	103	154	53	478
	Tax impact on Fair value changes on Equity investments through OCI	(15)	(28)	(7)	(87)
		89	**138**	**46**	**403**
	(ii). Items that will be reclassified to profit or loss:				
	Exchange differences on translating financial statements of foreign operations	1,088	682	347	2,518
	Share of OCI of associate (net of tax)	(67)	12	-	(47)
		1,021	**694**	**347**	**2,471**
	Other comprehensive income for the period/ year, net of tax	**1,110**	**832**	**393**	**2,874**
11	**Total comprehensive income for the period/ year (9+10)**	**3,175**	**3,522**	**5,196**	**17,059**
12	**Profit for the period/year attributable to:**				
	Owners of the Company	2,065	2,679	4,807	14,185
	Non-controlling interests	-	11	(4)	-
13	**Other comprehensive income for the period/ year attributable to:**				
	Owners of the Company	1,110	832	393	2,874
	Non-controlling interests	-	-	-	-
14	**Total comprehensive income for the period/ year attributable to:**				
	Owners of the Company	3,175	3,511	5,200	17,059
	Non-controlling interests	-	11	(4)	-
15	**Paid-up equity share capital (Face value of ₹2 each)**	**358**	**358**	**358**	**358**
16	**Other equity**				**91,853**
17	**Earnings per share (not annualised for the quarters) (Face value of ₹2 each)**				
	Basic (in ₹)	11.53	14.96	26.84	79.20
	Diluted (in ₹)	11.53	14.96	26.84	79.20

See accompanying notes to the unaudited consolidated financial results.

Continued..

NATCO Pharma Limited

Segment reporting:

(₹ in millions except per share data)

S.No.	Particulars	Quarter ended			Year ended
		30-06-2026	31-03-2026	30-06-2025	31-03-2026
		Unaudited	Audited (Refer note 4)	Unaudited	Audited
1	**Segment revenue**				
	a. Pharmaceuticals	6,944	7,165	12,942	39,401
	b. Agro chemicals	408	226	347	1,382
	Total revenue from operations	**7,352**	**7,391**	**13,289**	**40,783**
2	**Segment results**				
	a. Pharmaceuticals	2,039	1,554	5,783	15,473
	b. Agro chemicals	(53)	(4)	(32)	(198)
	Total segment result	**1,986**	**1,550**	**5,751**	**15,275**
	Less:				
	a. Finance costs	(130)	(109)	(32)	(367)
	b. Net unallocated (income)/expenditure	-	-	-	-
	Total profit before tax and share of profit of associate	**1,856**	**1,441**	**5,719**	**14,908**
3	**Segment assets**				
	a. Pharmaceuticals	99,003	96,759	54,626	96,759
	b. Agro chemicals	3,127	3,022	2,678	3,022
	Total segment assets	**1,02,130**	**99,781**	**57,304**	**99,781**
	Add:				
	a. Unallocated	10,215	10,956	34,687	10,956
	Total assets	**1,12,345**	**1,10,737**	**91,991**	**1,10,737**
4	**Segment liabilities**				
	a. Pharmaceuticals	14,857	14,913	7,401	14,913
	b. Agro chemicals	738	520	440	520
	Total segment liabilities	**15,595**	**15,433**	**7,841**	**15,433**
	Add:				
	a. Unallocated	1,365	3,093	2,833	3,093
	Total liabilities	**16,960**	**18,526**	**10,674**	**18,526**

Continued..

Unallocated assets includes investments and tax assets. Unallocated liabilities includes general borrowings and tax liabilities.

NATCO Pharma Limited

Notes to the unaudited consolidated financial results:

1) The unaudited consolidated financial results of NATCO Pharma Limited ("the Company") and its subsidiaries (the Company and its subsidiaries together referred as "the Group") and its associate have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
2) The unaudited consolidated financial results for the quarter ended 30-06-2026 have been reviewed by the Audit Committee of the Board and approved by the Board of Directors of the Company at their meetings held on 14-08-2026.
3) The unaudited consolidated financial results of the Group for the quarter ended 30-06-2026, have been reviewed by the statutory auditors and they have issued an unmodified review report on the same. The review report of the statutory auditors is being filed with the National Stock Exchange of India Limited ('NSE') and BSE Limited ('BSE') and is also available on the Company's website.
4) The consolidated figures for the quarter ended 31-03-2026 as reported in these unaudited consolidated financial results are the balancing figures between consolidated audited figures in respect of the full previous financial year and the published unaudited year to date consolidated figures up to the third quarter of the previous financial year. Also, the consolidated figures up to the end of the third quarter had only been reviewed and not subjected to audit.
5) The unaudited consolidated financial results for the quarter ended 30-06-2026 includes financial results of the following subsidiaries/step-down subsidiaries and associate Company:

S.No	Name of the entity	Country	Relationship
1	NATCO Pharma Inc.	United States of America	Wholly owned Subsidiary
2	NATCO Pharma USA LLC	United States of America	Step-down Subsidiary
3	Time Cap Overseas Limited	Mauritius	Wholly owned Subsidiary
4	NatcoFarma do Brasil Ltda.	Brazil	Step-down Subsidiary
5	NATCO Pharma (Canada) Inc.	Canada	Wholly owned Subsidiary
6	NATCO Pharma Asia Pte. Ltd.	Singapore	Wholly owned Subsidiary
7	NATCO Pharma Australia PTY Ltd.	Australia	Wholly owned Subsidiary
8	NATCO Lifesciences Philippines Inc.	Philippines	Wholly owned Subsidiary
9	NATCO Pharma UK Limited	United Kingdom	Wholly owned Subsidiary
10	PT.NATCO Lotus Farma	Indonesia	Wholly owned Subsidiary
11	NATCO Pharma Colombia S.A.S.	Colombia	Wholly owned Subsidiary
12	NATCO Pharma South Africa Proprietary Limited (incorporated on 31-07-2025)	South Africa	Wholly owned Subsidiary
13	Adcock Ingram Holdings Limited (w.e.f 11-11-2025)	South Africa	Associate company of NATCO Pharma South Africa Proprietary Limited
14	NATCO Crop Health Sciences Limited (incorporated on 26-12-2025)	India	Wholly owned Subsidiary

6) The unaudited standalone financial results, for the quarter ended 30-06-2026 can be viewed on the website of the Company, NSE and BSE at www.natcopharma.co.in, www.nseindia.com, and www.bseindia.com respectively. Information of unaudited standalone financial results of the Company in terms of Regulation 47(1)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is as under:

(₹ in millions)

Particulars	Quarter ended			Year ended
	30-06-2026	31-03-2026	30-06-2025	31-03-2026
	Unaudited	Audited (Refer note 4)	Unaudited	Audited
Total income	6,449	6,817	12,523	38,757
Profit before tax	1,020	1,100	5,429	13,641
Net profit for the period/ year	746	2,096	4,641	12,815
Total comprehensive income for the period/ year	853	2,232	4,680	13,083

7) The Board of Directors, at its meeting held on 08-07-2026, approved the acquisition of 19,618,825 shares of Adcock Ingram Holdings Limited ("Adcock"), South Africa, representing additional stake of 13.25% of its equity share capital through NATCO Pharma South Africa Proprietary Limited (wholly owned subsidiary in South Africa). The acquisition comprise of 19,618,825 ordinary shares, at a cash offer price of ZAR 92.50 per share. On 14-07-2025, NATCO Pharma South Africa Proprietary Limited completed the aforesaid acquisition for a total purchase consideration of ZAR 1,814.74 million (INR 10,600 million). With completion of this transaction, NATCO's shareholding in Adcock has increased from 35.75% to 49%.
8) The Board of Directors at its meeting held on 24-03-2026, approved (subject to the requisite and other approvals) a Scheme of Arrangement (Demerger) involving the demerger of its Agro Chemical business undertaking into NATCO Crop Health Sciences Limited (newly incorporated wholly owned subsidiary). The Scheme of Arrangement has been filed with relevant regulatory authorities and is pending for approval as at 30-06-2026.
9) The Company has elected to exercise the option permitted under Section 115BAA of the Income-tax Act, 1961 effective from financial year 2026-27, to be subject to tax at a rate of 22% plus applicable surcharge and cess. Accordingly, the Company has re-measured its deferred tax assets on minimum alternate tax credit and other deferred tax assets and liabilities based on the tax rate prescribed in the said Section in accordance with Ind AS 12 - Income Taxes. The impact of such measurement, amounting to INR 1,150 million, has been recognised as a deferred tax asset in the statement of profit and loss during the quarter and year ended 31-03-2026.
10) The Board of Directors at its meeting held on 14-08-2026 had approved an interim dividend of ₹ 1.50/- per equity share of ₹ 2 each for the quarter ended 30-06-2026.

For NATCO Pharma Limited

V C Nannapaneni
Chairman & Managing Director
(DIN: 00183315)

Place: Hyderabad
Date: 14 August 2026

B S R and Co
Chartered Accountants

Salarpuria Knowledge City, Orwell
B Wing, 6th Floor, Unit-3, Sy No. 83/1
Plot No. 02, Raidurg
Hyderabad – 500 081, India
Telephone + 91 407 182 2000
Fax + 91 407 182 2399

Limited Review Report on unaudited consolidated financial results of NATCO Pharma Limited for the quarter ended 30 June 2026 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of NATCO Pharma Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of NATCO Pharma Limited (hereinafter referred to as “the Parent”), and its subsidiaries (the Parent and its subsidiaries together referred to as “the Group”) and its share of the net profit after tax and total comprehensive income of its associate for the quarter ended 30 June 2026 (“the Statement”), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

2. This Statement, which is the responsibility of the Parent’s management and approved by the Parent’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “*Interim Financial Reporting*” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 *“Review of Interim Financial Information Performed by the Independent Auditor of the Entity”,* issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities

Name of the entity	Relationship
NATCO Pharma Limited	Parent
NATCO Pharma Inc., United States of America (USA)	Wholly owned Subsidiary
NATCO Pharma USA LLC, USA (Subsidiary of NATCO Pharma Inc.)	Step-down Subsidiary
Time Cap Overseas Limited, Mauritius (TCOL)	Wholly owned Subsidiary
NatcoFarma do Brasil Ltda., Brazil (Subsidiary of TCOL)	Step-down Subsidiary

Principal Office:
14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400063

NATCO Pharma (Canada) Inc., Canada	Wholly owned Subsidiary
NATCO Pharma Asia Pte. Ltd., Singapore	Wholly owned Subsidiary
NATCO Pharma Australia Pty Ltd, Australia	Wholly owned Subsidiary
NATCO Lifesciences Philippines Inc., Philippines	Wholly owned Subsidiary
NATCO Pharma UK Limited, United Kingdom	Wholly owned Subsidiary
PT. NATCO Lotus Farma, Indonesia	Wholly owned Subsidiary
NATCO Pharma Colombia S.A.S., Colombia	Wholly owned Subsidiary
NATCO Pharma South Africa Proprietary Limited, South Africa (Incorporated on 31 July 2025)	Wholly owned Subsidiary
NATCO Crop Health Sciences Limited, India (Incorporated on 26 December 2025)	Wholly owned Subsidiary
Adcock Ingram Holdings Limited (w.e.f. 11 November 2025), South Africa	Associate

5. Attention is drawn to the fact that the figures for the three months ended 31 March 2026 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.

6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

7. We did not review the interim financial information of 13 subsidiaries/step down subsidiaries included in the Statement, whose interim financial information reflect total revenues (before consolidation adjustments) of INR 2,466 million, total net profit after tax (before consolidation adjustments) of INR 530 million and total comprehensive income (before consolidation adjustments) of INR 531 million, for the quarter ended 30 June 2026, as considered in the Statement. The Statement also include the Group's share of net profit after tax of INR 843 million and total comprehensive income of INR 776 million, for the quarter ended 30 June 2026 as considered in the Statement, in respect of one associate, whose interim financial information has not been reviewed by us. These interim financial information have been reviewed by other auditors whose reports have been furnished to us by the Parent's management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries/step down subsidiaries and associate, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Certain of these subsidiaries/step down subsidiaries and associate located outside India whose interim financial information have been prepared in accordance with accounting principles generally accepted in their respective countries and which have been reviewed by other auditors under generally accepted auditing standards applicable in their respective countries. The Parent's management has converted the interim financial information of such subsidiaries/step down subsidiaries and associate located outside India from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India. We have reviewed these conversion adjustments made by the Parent's management. Our conclusion in so far as it relates to the balances and affairs of such subsidiaries/step down subsidiaries and associate located outside India is based on the reports of other auditors and the conversion adjustments prepared by the management of the Parent and reviewed by us.

Our conclusion is not modified in respect of this matter.

For **B S R and Co**

Chartered Accountants

Firm's Registration No.:128510W

AMIT KUMAR BAJAJ

Digitally signed by AMIT KUMAR BAJAJ
Date: 2026.08.14 13:32:03 +05'30'

Amit Kumar Bajaj

Partner

Membership No.: 218685

UDIN:26218685JWXPAY8868

Udaipur

14 August 2026

NATCO

NATCO Pharma Limited

Regd. Office: Natco House, Road No. 2, Banjara Hills, Hyderabad, Telangana - 500 034

Phone: +91-40-2354 7532, Website : www.natcopharma.co.in, CIN: L24230TG1981PLC003201

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30-06-2026

(₹ in millions except per share data)

S.No.	Particulars	Quarter ended			Year ended
		30-06-2026	31-03-2026	30-06-2025	31-03-2026
		Unaudited	Audited (Refer note 4)	Unaudited	Audited
	Income				
1	Revenue from operations	5,966	6,088	11,927	35,946
2	Other income	483	729	596	2,811
3	**Total income (1+2)**	**6,449**	**6,817**	**12,523**	**38,757**
4	**Expenses**				
	Cost of materials consumed	1,578	1,028	1,806	5,935
	Purchases of stock-in-trade	4	133	79	494
	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(15)	77	(48)	(692)
	Employee benefits expense	1,514	1,331	1,435	5,917
	Finance costs	96	97	26	323
	Depreciation, amortisation and impairment expense	427	456	538	1,896
	Other expenses	1,825	2,595	3,258	11,243
	Total expenses	**5,429**	**5,717**	**7,094**	**25,116**
5	**Profit before tax for the period/ year (3-4)**	**1,020**	**1,100**	**5,429**	**13,641**
6	**Tax expense**				
	(i) Current tax	110	56	1,060	2,684
	(ii) Deferred tax (refer note 8)	164	(1,052)	(272)	(1,858)
	Total tax expense	**274**	**(996)**	**788**	**826**
7	**Profit for the period/ year (5-6)**	**746**	**2,096**	**4,641**	**12,815**
8	**Other comprehensive income/ (loss) ('OCI') (net of tax)**				
	Items that will not be reclassified to profit or loss:				
	Remeasurement of defined benefit liability/(asset)	-	19	-	19
	Tax on remeasurement of defined benefit liability/(asset)	-	(7)	-	(7)
	Fair value changes in Equity investments through OCI	125	151	46	306
	Tax impact on Fair value changes in Equity investments through OCI	(18)	(27)	(7)	(50)
	Other comprehensive income for the period/ year, net of tax	**107**	**136**	**39**	**268**
9	**Total comprehensive income for the period/ year (7+8)**	**853**	**2,232**	**4,680**	**13,083**
10	**Paid-up equity share capital (Face value of ₹2 each)**	358	358	358	358
11	**Other equity**				85,168
12	**Earnings per share (not annualised for the quarters) (Face value of ₹2 each)**				
	Basic (in ₹)	4.17	11.70	25.91	71.55
	Diluted (in ₹)	4.17	11.70	25.91	71.55

See accompanying notes to the unaudited standalone financial results.

NATCO Pharma Limited

Notes to the unaudited standalone financial results:

1) The unaudited standalone financial results of NATCO Pharma Limited ("the Company") have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
2) The unaudited standalone financial results for the quarter ended 30-06-2026 have been reviewed by the Audit Committee of the Board and approved by the Board of Directors of the Company at their meetings held on 14-08-2026.
3) The unaudited standalone financial results of the Company for the quarter ended 30-06-2026, have been reviewed by the statutory auditors and they have issued an unmodified review report on the same. The review report of the statutory auditors is being filed with the National Stock Exchange of India Limited ('NSE') and BSE Limited ('BSE') and is also available on the Company's website.
4) The standalone figures for the quarter ended 31-03-2026 as reported in these unaudited standalone financial results are the balancing figures between standalone audited figures in respect of the full previous financial year and the published unaudited year to date standalone figures up to the third quarter of the previous financial year. Also, the figures up to the end of the third quarter of the previous financial year had only been reviewed and not subjected to audit.
5) Where financial results contain both consolidated and standalone financial results of the parent, segment information is required to be presented only in the consolidated financial results. Accordingly, segment information has been presented in the unaudited consolidated financial results.
6) The unaudited financial results of the following subsidiaries, step-down subsidiaries and associate of the Company are included in the consolidated financial results for the quarter ended 30-06-2026:

S.No	Name of the entity	Country	Relationship
1	NATCO Pharma Inc.	United States of America	Wholly owned Subsidiary
2	NATCO Pharma USA LLC	United States of America	Step-down Subsidiary
3	Time Cap Overseas Limited	Mauritius	Wholly owned Subsidiary
4	NatcoFarma do Brasil Ltda.	Brazil	Step-down Subsidiary
5	NATCO Pharma (Canada) Inc.	Canada	Wholly owned Subsidiary
6	NATCO Pharma Asia Pte. Ltd.	Singapore	Wholly owned Subsidiary
7	NATCO Pharma Australia PTY Ltd.	Australia	Wholly owned Subsidiary
8	NATCO Lifesciences Philippines Inc.	Philippines	Wholly owned Subsidiary
9	NATCO Pharma UK Limited	United Kingdom	Wholly owned Subsidiary
10	PT.NATCO Lotus Farma	Indonesia	Wholly owned Subsidiary
11	NATCO Pharma Colombia S.A.S.	Colombia	Wholly owned Subsidiary
12	NATCO Pharma South Africa Proprietary Limited (incorporated on 31-07-2025)	South Africa	Wholly owned Subsidiary
13	Adcock Ingram Holdings Limited (w.e.f 11-11-2025)	South Africa	Associate company of NATCO Pharma South Africa Proprietary Limited
14	NATCO Crop Health Sciences Limited (incorporated on 26-12-2025)	India	Wholly owned Subsidiary

7) The Board of Directors at its meeting held on 24-03-2026, approved (subject to the requisite and other approvals) a Scheme of Arrangement (Demerger) involving the demerger of its Agro Chemical business undertaking into NATCO Crop Health Sciences Limited (newly incorporated wholly owned subsidiary). The Scheme of Arrangement has been filed with relevant regulatory authorities and is pending for approval as at 30-06-2026.
8) During the quarter ended 31-03-2026, the Company elected to exercise the option permitted under Section 115BAA of the Income-tax Act, 1961 effective from financial year 2026-27, to be subject to tax at a rate of 22% plus applicable surcharge and cess. Accordingly, the Company re-measured its deferred tax assets on minimum alternate tax credit and other deferred tax assets and liabilities based on the tax rate prescribed in the said Section in accordance with Ind AS 12 - Income Taxes. The impact of such measurement, amounting to INR 1,150 million, was recognised as a deferred tax asset in the statement of profit and loss during the quarter and year ended 31-03-2026.
9) The Board of Directors, at its meeting held on 08-07-2026, approved the acquisition of 19,618,825 shares of Adcock Ingram Holdings Limited ("Adcock"), South Africa, representing additional stake of 13.25% of its equity share capital through NATCO Pharma South Africa Proprietary Limited (wholly owned subsidiary in South Africa). The acquisition comprise of 19,618,825 ordinary shares, at a cash offer price of ZAR 92.50 per share. On 14-07-2025, NATCO Pharma South Africa Proprietary Limited completed the aforesaid acquisition for a total purchase consideration of ZAR 1,814.74 million (INR 10,600 million). With completion of this transaction, NATCO's shareholding in Adcock has increased from 35.75% to 49%.
10) The Board of Directors at its meeting held on 14-08-2026 had approved an interim dividend of ₹ 1.50/- per equity share of ₹ 2 each for the quarter ended 30-06-2026.

By order of the Board
For NATCO Pharma Limited

V C Nannapaneni
Chairman & Managing Director
(DIN: 00183315)

Place: Hyderabad
Date: 14 August 2026

B S R and Co
Chartered Accountants

Salarpuria Knowledge City, Orwell
B Wing, 6th Floor, Unit-3, Sy No. 83/1
Plot No. 02, Raidurg
Hyderabad – 500 081, India
Telephone + 91 407 182 2000
Fax + 91 407 182 2399

Limited Review Report on unaudited standalone financial results of NATCO Pharma Limited for the quarter ended 30 June 2026 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of NATCO Pharma Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of NATCO Pharma Limited (hereinafter referred to as "the Company") for the quarter ended 30 June 2026 ("the Statement").

2. This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 *"Review of Interim Financial Information Performed by the Independent Auditor of the Entity"*, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Attention is drawn to the fact that the figures for the three months ended 31 March 2026 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.

5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it

Principal Office:

14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400063

contains any material misstatement.

For **B S R and Co**
Chartered Accountants
Firm's Registration No.:128510W

AMIT KUMAR BAJAJ
Digitally signed by AMIT KUMAR BAJAJ
Date: 2026.08.14 13:32:35 +05'30'

Amit Kumar Bajaj
Partner
Membership No.: 218685
UDIN:26218685MNMBPZ2642

Udaipur
14 August 2026

Press Release

NATCO

NATCO Pharma Ltd

NATCO House
Road No.2, Banjara Hills
Hyderabad-500 034, India

Hyderabad, India, August 14th, 2026: NATCO Pharma Limited (BSE: 524816 and NSE: NATCOPHARM) ("NATCO") today announced results for first quarter of financial year 2027.

NATCO records ₹794.4 Crore consolidated revenue and ₹206.5 Crore of profit after tax for Q1 FY27

- NATCO recorded consolidated total revenue of INR 794.4 Crore for the quarter ended on 30th June 2026, as against INR 1,390.6 Crore for the corresponding quarter last year. Decline is largely attributable to lower Lenalidomide revenue in the current quarter which was partially offset by growth in the base business. The net profit for the period, on a consolidated basis, was INR 206.5 Crore, as against INR 480.3 Crore for the corresponding quarter last year.

- For the quarter, revenue of the associate company, Adcock Ingram Holdings Limited, South Africa was at INR 1,582.8 crores and profit after tax was at INR 242.2 crores. NATCO's share of profit based on the holding as on 30th June 2026 of 35.75% stood at INR 84.3 crores. In July 2026, NATCO acquired additional 13.25% stake in Adcock Ingram Holding Limited taking the total holdings to 49%.

- The Board of Directors have declared an interim dividend of INR 1.5 per equity share of INR 2 each during Q1FY27.

Segmental Revenue Split (INR Crore)

Business Segments	Q1FY27	Q1FY26
Active Pharmaceutical Ingredients (API)	66.7	52.6
Domestic Pharmaceutical Formulations	136.4	107.0
International Formulations (Incl. profit share and subsidiaries)	477.1	1,120.9
Crop Health Sciences (CHS)	40.8	34.7
Other operating and non-operating income	73.4	75.4
Total	**794.4**	**1,390.6**

NATCO Pharma Ltd

NATCO House
Road No.2, Banjara Hills
Hyderabad-500 034, India

About NATCO Pharma Limited

NATCO Pharma Limited (www.natcopharma.com), (NSE:NATCOPHARM, BSE: 524816, Reuters: NATP.NS, Bloomberg: NTCPH,) headquartered at Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharma ingredients and crop protection products. The Company is a R&D oriented, and a science driven, leading Oncology player in the targeted therapies of domestic market and focuses on limited competition molecule in the US. The Company's different manufacturing facilities are approved by several leading regulatory authorities like US FDA, Brazil ANVISA, Health Canada, WHO and others catering to 50+ global markets. For more information, please visit us at www.natcopharma.com or click on LinkedIn or X (formerly Twitter).

Earnings Call Details:

- *Date: 14th August 2026, Friday*
- *Time: 5.30 PM IST*
- ***Dial-in-Numbers:***
    - *India: (+91 22) 62801222 / 71158123*
    - *US: 18667462133*
    - *UK: 08081011573*
    - *Singapore: 8001012045*
    - ***Diamond pass link:*** https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=8730033&linkSecurityString=43c052c9f4

For further information please contact:

Rajeev Menon - Investor Relations

ir@natcopharma.co.in/r.menon@natcopharma.co.in